Response rate. OS data. Toxicity. Infusion schedule. Supportive medications.
Dr. Garrido-Castro breaks down how all these factors shape real-world selection between the two TROP2 ADCs for first-line metastatic TNBC.
How Clinicians Choose Between TROP2 ADCs
You may also like
Recommended Videos
